JNJ Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 20.83% compared to Johnson & Johnson's net margin of 27.55%. Johnson & Johnson's return on equity of 34.46% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Johnson & Johnson has a consensus price target of $232.50, signalling downside risk potential of -4.12%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $155.41 which suggests that it could grow by 2.65%. Given that Gilead Sciences, Inc. has higher upside potential than Johnson & Johnson, analysts believe Gilead Sciences, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.350, which suggesting that the stock is 64.977% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.12%. Gilead Sciences, Inc. offers a yield of 2.09% to investors and pays a quarterly dividend of $0.79 per share. Johnson & Johnson pays 46.59% of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24.6B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.9B. Johnson & Johnson's net income of $5.1B is higher than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Johnson & Johnson's price-to-earnings ratio is 21.95x while Gilead Sciences, Inc.'s PE ratio is 22.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 6.25x versus 6.46x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 20.83% compared to Johnson & Johnson's net margin of 34.4%. Johnson & Johnson's return on equity of 34.46% beat Eli Lilly & Co.'s return on equity of 104.39%.

Johnson & Johnson has a consensus price target of $232.50, signalling downside risk potential of -4.12%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Eli Lilly & Co. has higher upside potential than Johnson & Johnson, analysts believe Eli Lilly & Co. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.350, which suggesting that the stock is 64.977% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.12%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Johnson & Johnson pays 46.59% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24.6B, which are larger than Eli Lilly & Co. quarterly revenues of $19.3B. Johnson & Johnson's net income of $5.1B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Johnson & Johnson's price-to-earnings ratio is 21.95x while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 6.25x versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 20.83% compared to Johnson & Johnson's net margin of -121.83%. Johnson & Johnson's return on equity of 34.46% beat Moderna, Inc.'s return on equity of -29.19%.

Johnson & Johnson has a consensus price target of $232.50, signalling downside risk potential of -4.12%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16.28%. Given that Moderna, Inc. has more downside risk than Johnson & Johnson, analysts believe Johnson & Johnson is more attractive than Moderna, Inc..

Johnson & Johnson has a beta of 0.350, which suggesting that the stock is 64.977% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.12%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 46.59% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24.6B, which are larger than Moderna, Inc. quarterly revenues of $678M. Johnson & Johnson's net income of $5.1B is higher than Moderna, Inc.'s net income of -$826M. Notably, Johnson & Johnson's price-to-earnings ratio is 21.95x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 6.25x versus 9.98x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 20.83% compared to Johnson & Johnson's net margin of 21.74%. Johnson & Johnson's return on equity of 34.46% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Johnson & Johnson has a consensus price target of $232.50, signalling downside risk potential of -4.12%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.58%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.350, which suggesting that the stock is 64.977% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.12%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Johnson & Johnson pays 46.59% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24.6B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Johnson & Johnson's net income of $5.1B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Johnson & Johnson's price-to-earnings ratio is 21.95x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 6.25x versus 5.90x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.